MBMeenakshi Bewtra

Meenakshi Bewtra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meenakshi Bewtra has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • James D. Lewis

    Department of Gastroenterology, University of Pennsylvania, Philadelphia, PA

    3 shared publications
  • Corey A. Siegel

    ‡Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

    2 shared publications
  • F. Reed Johnson

    ‡RTI-HS, Research Triangle Institute, Research Triangle Park, North Carolina

    2 shared publications
  • Kimberly A. Forde

    Department of Gastroenterology, University of Pennsylvania, Philadelphia, PA

    2 shared publications
  • Angelyn Fairchild

    1 shared publication
  • Angelyn O Fairchild

    RTI-HS, Research Triangle Institute, Research Triangle Park, North Carolina, USA

    1 shared publication

Latest Publications

  • Women's Preferences for IBD Medical Therapy during Pregnancy

    by Angelyn Fairchild, Tatyana Kushner, F. Reed Johnson, Bruce E. Sands, Uma Mahadevan, Ashwin Ananthakrishnan, Christina Y. Ha, Meenakshi Bewtra


  • Inflammatory Bowel Disease Patients’ Willingness to Accept Medication Risk to Avoid Future Disease Relapse

    by Meenakshi Bewtra, Angelyn O Fairchild, Erin Gilroy, David A Leiman, Caroline Kerner, Reed F Johnson, James D Lewis

    The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)


  • Mortality Associated With Medical Therapy Versus Elective Colectomy in Ulcerative Colitis

    by Meenakshi Bewtra, Craig W. Newcomb, Qufei Wu, Lang Chen, Fenglong Xie, Jason A. Roy, Cary B. Aarons, Mark T. Osterman, Kimberly A. Forde, Jeffrey R. Curtis, et al.

    Ulcerative colitis (UC) can be treated with surgery or medications. Patients often must choose between long-term immunosuppressant therapy or total colectomy. Whether one of these treatment approaches has a mortality benefit is uncertain. To determine whether patients with advanced UC treated with elective colectomy have improved survival compared with those treated with medical therapy. Retrospective matched cohort study. Data from all 50 states for Medicaid beneficiaries (2000 to 2005), Medicare beneficiaries (2006 to 2011), and dual-eligible persons (2000 to 2011). 830 patients with UC pursuing elective colectomy and 7541 matched patients with UC pursuing medical therapy. The primary outcome was time to death. Cox proportional hazards models were used to compare the survival of patients with advanced UC treated with elective colectomy or medical therapy. The models controlled for significant comorbid conditions through matched and adjusted analysis. The mortality rates associated with elective surgery and medical therapy were 34 and 54 deaths per 1000 person-years, respectively. Elective colectomy was associated with improved survival compared with long-term medical therapy (adjusted hazard ratio [HR], 0.67 [95% CI, 0.52 to 0.87]), although this result did not remain statistically significant in all sensitivity analyses. Post hoc analysis by age group showed improved survival with surgery in patients aged 50 years or older with advanced UC (HR, 0.60 [CI, 0.45 to 0.79]; P = 0.032 for age-by-treatment interaction). Retrospective nonrandomized analysis is subject to residual confounding. The source cohort was derived from different databases throughout the study. Sensitivity and secondary analyses had reduced statistical power. Elective colectomy seemed to be associated with improved survival relative to medical therapy among patients aged 50 years or older with advanced UC. National Institutes of Health and Agency for Healthcare Research and Quality.


  • An Optimized Patient-reported Ulcerative Colitis Disease Activity Measure Derived from the Mayo Score and the Simple Clinical Colitis Activity Index

    by Meenakshi Bewtra, Colleen M. Brensinger, Vesselin T. Tomov, Tram B. Hoang, Carly E. Sokach, Corey A. Siegel, James D. Lewis

    There is a need for simple, noninvasive patient-driven disease assessment instruments in ulcerative colitis (UC). We sought to further assess and refine the previous described 6-point Mayo score. A cross-sectional study of 282 UC patients was conducted assessing the correlation of the 2 patient-reported Mayo score components (6-point Mayo score) with the simple clinical colitis activity index (SCCAI) and a single Likert scale of patient-reported disease activity. Spearman's correlation, sensitivity, specificity, and area under the receiver operating curves (AUC) were calculated. A separate validation study in 59 UC patients was also conducted. Participants predominantly had long-standing disease (83%) and were in self-reported remission (63%). The 6-point Mayo score correlated well with the SCCAI (rho = 0.71; P < 0.0001) and patient-reported disease activity (rho = 0.65; P < 0.0001). Using a cutpoint of 1.5, the 6-point Mayo score had 83% sensitivity and 72% specificity for patient-defined remission, and 89% sensitivity and 67% specificity for SCCAI-defined remission (score, <2.5). The 6-point Mayo score and SCCAI had similar accuracy of predicting patient-defined remission (AUC = 0.84 and 0.87, respectively). Addition of the SCCAI general well-being question to the 6-point Mayo improved the predictive ability for patient-defined remission; and a new weighted score had an AUC of 0.89 in the development cohort and 0.93 in the validation cohort. The optimal cutpoint was 1.6. The patient-reported UC severity index that includes stool frequency, bleeding, and general well-being accurately measures clinical disease activity without requiring direct physician contact.


  • Open Access

    Patient Preferences for Surgical Versus Medical Therapy for Ulcerative Colitis

    by Meenakshi Bewtra, Vikram Kilambi, Angelyn O. Fairchild, Corey A. Siegel, James D. Lewis, F. Reed Johnson

    Background. Therapy options for mesalamine-refractory ulcerative colitis (UC) include immunosuppressive medications or surgery. Chronic immunosuppressive therap


  • Assessing Patient Preferences for Treatment Options and Process of Care in Inflammatory Bowel Disease: A Critical Review of Quantitative Data

    by Meenakshi Bewtra, F. Reed Johnson

    Inflammatory bowel disease (IBD), consisting of both Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the intestinal tract. As there is no cure for either CD or UC, patients with these conditions face numerous treatment decisions regarding their disease. The aim of this review is to evaluate literature regarding quantitative studies of patient preferences in therapy for IBD with a focus on the emerging technique of stated preference and its application in IBD. Numerous simple survey-based studies have been performed evaluating IBD patients’ preferences for medication frequency, mode of delivery, potential adverse events, etc., as well as variations in these preferences. These studies are limited, however, as they are purely descriptive in nature with limited quantitative information on the relative value of treatment alternatives. Time trade-off and standard-gamble studies have also been utilized to quantify patient utility for various treatment options or outcomes. However, these types of studies suffer from inaccurate assumptions regarding patient choice behavior. Stated preference is an emerging robust methodology increasingly utilized in health care that can determine the relative utility for a therapy option as well as its specific attributes (such as efficacy or adverse side effects). Stated preference techniques have begun to be applied in IBD and offer an innovative way of examining the numerous therapy options these patients and their providers face.


  • Mo1922 Adherence to the 2011 AGA Medical Position Statement for the Diagnosis, Screening, and Surveillance of Barrett's Esophagus

    by Audrey K. Menezes, Ann Tierney, Yu-Xiao Yang, Kimberly A. Forde, Meenakshi Bewtra, David C. Metz, Gregory G. Ginsberg, Gary W. Falk